Dept of Health Abu Dhabi and Pfizer Partner To Research in Sickle Cell Disease

During the BIO 2024 International Convention, the Department of Health – Abu Dhabi (DoH), the Emirate's healthcare regulator, entered into a Memorandum of Understanding (MoU) with Pfizer Gulf FZ LLC, a global pharmaceutical firm.

Under the statement, the entities will attempt to upgrade Abu Dhabi's situation as driving worldwide center point for medical care, life science and advancement. Utilizing the Emirate's interesting capacities and future-forward information administrations as well as Pfizer's worldwide abilities, the parties look to propel research through the age and examination of real-world data (RWD) at first focusing on sickle cell illness (SCD) and growing to other illness regions to help patients locally, provincially and beyond.

Within the sight of H.E. Mansoor Al Mansoori, chairman of the Department of Health – Abu Dhabi (DoH) the MoU was endorsed by Dr Asma Al Mannaei, the executive director of the research and innovation centre at DoH and Serhat Yalcinkaya, Pfizer’s Gulf Cluster Lead.

Dr Asma Ibrahim Al Mannaei, executive director of the research and innovation center at the at DoH said: “The collaboration between the DoH and Pfizer represents a significant step towards harnessing real-world data in the region and better understanding patient populations from the vast available data in Abu Dhabi. By partnering with Pfizer on real-world data, we aim to drive advancements in healthcare prediction, prevention, personalised treatment and access, not only benefiting healthcare professionals and patients in Abu Dhabi, but also contributing to the improvement of care for patients globally.”